CVX

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✓

Return

+0.20%

Status

scored

Maintain CVX at 75-80% ATR-adjusted integrated-energy allocation—do not add at $211.55 given light-volume breakout into $217.77 resistance, 14.1% premium to the 200 SMA, and MACD divergence. Pre-commit buys at $195-200 (50 SMA zone, 50% size) and $185-190 (200 SMA zone, full size), trim 10-15% into $215-218 rallies, hold covered calls $215-220 Dec expiry to monetize IV, and set hard stop at $183 daily close. Q3 2026 earnings (late Oct/early Nov) is the binary catalyst—Overweight on print above $5.00 EPS, Underweight on print below $4.00.

Outcome

✗

Return

+3.12%

Status

scored

Maintain CVX at Hold with benchmark-to-modest overweight positioning; pre-commit limit orders at $199-200 for 25-50% incremental adds and trim 10-15% into $213-217 rallies pre-Q3 earnings. Hard stop set at $196 daily close; reinvest the 3.43% dividend and hold covered calls at $215-220 (Dec expiry) to capture chop alpha. Q3 2026 earnings (late October/early November) is the binary resolution catalyst.

Outcome

✓

Return

-1.17%

Status

scored

Maintain CVX at 75-80% of standard integrated-energy allocation while staging pre-committed limit orders at $200-203 for a 25-50% incremental add rather than chasing the current $207.58 entry; reject aggressive 15-20% add and neutral 10-15% tactical add calls as both reproduce the discretionary confirmation framework the prior reflection explicitly warned against. Hold covered calls at $215-220 (Dec expiry) to monetize elevated IV with a hard stop at $199.92 daily close; Q3 2026 earnings (Oct 31) is the binary catalyst.

Outcome

✓

Return

+0.54%

Status

scored

Maintain CVX position unchanged in the $204-208 range with a Hold rating as the structural uptrend (50 SMA leading 200 SMA by ~$18, 6.3% total shareholder yield, 37-year Aristocrat streak) offsets elevated valuation risk (TTM P/E 19.87 at top of $190-$205 fair-value range, MACD below signal). Do not add above $205 without confirmed reversal, do not trim at current levels, and let Q3 2026 earnings on Oct 31 resolve the Q2 contamination debate before reassessing.

Outcome

–

Return

-0.11%

Status

scored

Analysts recommend trimming 10-15% of CVX exposure at $205-208, rejecting the Trader's proposed 25-40% reduction, as five consecutive CVX calls (Sept 22-Oct 1) produced alpha clustered around ±1% despite correct directional reads. The structural floor—0.49 beta, 37-year Aristocrat streak, intact 200 SMA at $184.13, and sub-1x leverage—compresses realized alpha toward noise regardless of directional conviction, making the aggressive magnitude an error. Hard stop at $199 daily close, with Q3 2026 earnings (early November) serving as the binary re-rating catalyst.

Outcome

–

Return

-0.20%

Status

scored

Trim 10-15% of CVX exposure at or near current levels ($207.10) or on a retest of the 10 EMA at $206.22, rejecting the trader's higher entry proposal of $209.50. Place a hard stop on the remaining 85-90% of the position at the 50 SMA ($201.66) daily close; the trader's $213.80 stop is internally contradictory as it sits above entry on a bearish trade. Reassess at Q3 2026 earnings in late October/early November as the binary catalyst.

Outcome

✗

Return

+1.42%

Status

scored

Analysts converge on HOLD for CVX at ~$204 given mixed signals—the structural stack (Guyana Stabroek, 0.49 beta, 3.48% dividend yield, 6.5% total shareholder yield, 200 SMA floor at $183.52) supports retention, but near-term tactical headwinds (MACD bearish cross, September 18 distribution event with 47.3M shares, Q2 EPS inflated 75-145% by Hess remeasurement) counsel against adding. Position sizing is reduced to 75-80% of standard allocation given elevated ATR at $4.15, with formal reassessment at Q3 2026 earnings in early November.

Outcome

✓

Return

-0.08%

Status

scored

Maintain CVX at current levels without adding at $204; the structural thesis (Guyana runway, fortress balance sheet, 37-year Aristocrat streak) remains intact but the entry point is poor given MACD still expanding negative and Q2 EPS sugar high not yet discounted. Three-tier scale-in framework (at $200-202, $206, $209) with mandatory momentum confirmation replaces single-entry aggression. Separate thesis-breaker trim ($200 close) from catastrophic-loss stop ($195 close) provides mechanical discipline absent in prior Hold failures. Q3 2026 earnings is framed as an information event, not a binary verdict, with $230 price target (17x normalized EPS of $13.57) as 12-month anchor.

Outcome

✓

Return

-0.96%

Status

scored

Maintain CVX exposure at current levels without adding at $206, as the plan explicitly directs accumulation at $190–$200 and five consecutive CVX calls produced only marginal alpha (<1%) due to the structural floor absorbing downside while capping upside. Preserve capital for three potential re-engagement entries: Tier 1 at $200–$210 consolidation with RSI >50, Tier 2 at $190–$195 pullback with RSI <45, or Tier 3 at $183 200 SMA tag, with breakout override above $217 upgrading to Overweight. Hold covered calls at $215–$220 (Dec expiry) to monetize elevated IV; reassess at Q3 2026 earnings as the next binary decision point.

Outcome

✓

Return

+0.94%

Status

scored

Adopt a 30% initial tranche at $203-205 with 30% at the $200.31/$200.63 confluence zone (requires MACD histogram compression toward zero), reserving 40% for either a $195.84 July-low flush or confirmed 10 EMA reclaim at ~$207; overall sizing at 75-80% of standard integrated-energy allocation due to ATR running 12% above baseline, with hard stop at $195.84 daily close and structural exit at $182.64 weekly close.

Outcome

✓

Return

-0.58%

Status

scored

Trim ~15% of CVX near $207 (10 EMA zone) rather than the proposed 25-33% at $210-212, as the higher-fill probability zone is preferred over overhead resistance. Hold remaining 85% with a daily-close stop at $199.42 (50 SMA) that triggers further 15% trim on confirmed breakdown; proceed with Q3 2026 earnings as the next binary decision point while parking trimmed proceeds in short-duration Treasuries rather than forcing redeployment in the hostile macro environment.

Outcome

–

Return

+0.07%

Status

scored

Scale into CVX with an Overweight rating using a disciplined two-tranche approach: deploy 20-25% of new capital at $204-206 and reserve 75-80% for the $198-200 primary buy zone, with a tighter tactical stop at $195 on the initial tranche and re-anchoring to $188 once fully positioned. Buy $190 puts (3-6 month) as cheap insurance against unresolved distribution signature. The structural bull case (sub-1x Net Debt/EBITDA, 37-year dividend Aristocrat streak, 0.49 beta, $40.1B → $28.5B balance sheet transformation) outweighs tactical risks (MACD histogram at -1.47, RSI at 49.4, Sep 18 distribution candle), warranting measured accumulation rather than aggressive Buy commitment.

Outcome

✓

Return

+1.53%

Status

scored

Scale into CVX at $195-197 (Tier 1) or $193-196 on confirmation (Tier 2), with a stop at $192.50 honored on daily close only. Position sizing is 50% of standard allocation with WTI $80 strike puts as a ~1% portfolio hedge, targeting $230 in 3-6 months while reassessing at Q3 2026 earnings.

Outcome

✓

Return

-0.62%

Status

scored

Trim CVX by 25-30% via staged execution over 2-3 sessions, retaining 70-75% core position. Hedge the retained exposure by selling covered calls at $215-220 strikes to monetize elevated implied volatility rather than buying puts. Hard stop at $181.48 weekly close (200 SMA); defensive trigger at $195 close on volume >10M triggers additional 15% trim. Re-enter only on confirmed close above $209.91 (10 EMA) with RSI reclaiming 50 and MACD histogram turning positive—no pre-committing to lower levels. Formal re-evaluation at Q3 2026 earnings; collect 3.4% dividend yield as carry while waiting.

Outcome

✗

Return

-2.79%

Status

scored

Maintain CVX at benchmark weight given 1.8:1 risk/reward with modest positive skew — the $240 PT and $22.6B Q2 FCF support the structural case, but 47.2M share distribution, MACD bearish cross, and 14.5% Hess dilution near peak $6.11 EPS warrant defensive discipline rather than aggressive addition. Collect the 3.37% dividend carry while enforcing mechanical triggers: trim 15-25% below $197.84 (50 SMA), exit 50%+ below $181.19 (200 SMA), and add on breakout above $217.77 with volume confirmation.

Outcome

✗

Return

-0.97%

Status

scored

Overweight rating on CVX with disciplined staged entry anchored to weakness at $200 rather than chasing current $211 price; cap full deployment at 1.25% NAV to manage cyclical commodity concentration. Stop at $194.50 close with hard exit below $180.88; trim 25-30% on confirmed close above $219.05 with volume ≥10M. Hard review if WTI breaks $97 on weekly close; Q3 2026 earnings is the binary catalyst.

Outcome

–

Return

+0.01%

Status

scored

Analysts converge on Underweight with a 25-35% trim in the $211-220 zone while retaining 65-75% core exposure for structural participation. Hard stop at $195 (50 SMA break) limits downside, with full re-evaluation at Q3 2026 earnings (late October) and cross-ticker rotation to XOM or COP as optional alternatives.

Outcome

✓

Return

-2.86%

Status

scored

The analysts unanimously recommend trimming CVX to 65% of benchmark weight via a three-tranche execution in the $213–$220 zone, driven by five convergent bearish factors: a +20.81% premium to the 200 SMA with historically poor forward returns, Q2 2026 EPS inflated by a 27% tax rate and $2.99B in non-recurring income, geopolitical oil spike mean-reversion risk, late-cycle technical deterioration with MACD compression and RSI divergence, and structural underperformance versus refiner-led rotations. The hard stop sits at $195.58 (50 SMA, 2.2 ATR), with re-evaluation scheduled for Q3 2026 earnings in late October.

Outcome

✗

Return

+2.64%

Status

scored

Maintain existing CVX position unchanged as the structural floor (0.56x Net Debt/EBITDA, 3.33% Aristocrat yield, 0.49 trailing beta, $18.1B Q2 2026 FCF) remains intact. Do NOT initiate new capital at $212+; instead deploy a three-tranche scaling framework with reduced sizing (25-30% below standard) triggered by pullback to $200-205 with RSI reset to 55-60, or confirmed daily close above $217.65 on volume >10M shares. Trail hard stop to $194.56 (50 SMA), monitor Polymarket pipeline-restart probability daily for geopolitical risk management, and reassess at Q3 2026 earnings.

Outcome

✓

Return

-0.88%

Status

scored

Trim approximately 25% of CVX exposure in the $212-216 zone while retaining 75% core position, with a hard stop at $205 (2.2 ATR below current) rather than the tighter $200 stop to avoid gap-stop whipsaw given ATR of $4.15. Re-enter on pullback to $200-205 zone with RSI reset to 55-60, or on 50 SMA test at $193-197 with MACD histogram confirming reversal, reassessing at Q3 2026 earnings in late October.

Outcome

✓

Return

+0.61%

Status

scored

Analysts unanimously maintain CVX at Hold given the 15.79x forward P/E at 52-week highs is fairly valued, not mispriced. The recommended approach uses a three-tranche scaling framework—25-30% starter at $212-213, 40-50% reserved for the $200-205 pullback zone, and 20-25% for the $192-195 deep pullback—to target a blended cost basis of $200-205. Key catalysts include Q3 2026 earnings (late October) and a $190 hard stop that would invalidate the Golden Cross structure, with a $225 price target over a 3-6 month tactical horizon.

Outcome

–

Return

-0.49%

Status

scored

Trim CVX 25-35% in tranches into the $215-220 zone (one-third near $213, one-third on push to $215-218, final third on test of $218-220 with volume >10M), cancel unfilled tranches if price gaps below $208. Retain residual core at 60-70% of benchmark weight with trailing stop tightened to $206 (blended 10 EMA/Bollinger midline) versus the Conservative's $191.70 stop. Do not initiate new long positions until a 10%+ pullback or Q3 2026 earnings validates the Q2 EPS power as structural.

Outcome

✓

Return

+1.91%

Status

scored

Initiate staged CVX accumulation targeting 2-2.5% portfolio cap: 0.5% starter at $209.80, 0.5% add in the $203-207 pullback zone, and reserve 0.5%-1.0% for $195-200 or a confirmed breakout above $214.24. Overweight rating balances structural conviction (Hess synergies, Guyana exposure, 0.6-0.8x Net Debt/EBITDA, 15.6x forward P/E, 3.4% yield) against suboptimal entry timing at current levels, justifying staged scaling over market-loading commitment or passive Hold.

Outcome

✓

Return

+0.58%

Status

scored

Overweight CVX with a three-tranche scaling framework targeting $185-205 pullback zones while avoiding entry at current $208+ levels. The $165 hard stop provides downside protection for a low-beta (0.49) position, with Q3 2026 earnings as the primary reassessment catalyst for escalating or trimming the 60-70% full energy allocation target.

Outcome

✓

Return

-1.29%

Status

scored

Maintain CVX at current portfolio weight without adding at $211; the structural thesis (Hess/Guyana, 0.8x Net Debt/EBITDA, 35 consecutive dividend increases) is intact but technical signals (RSI 71.15, MACD deceleration, Bollinger upper band rejection at $214.84) argue for waiting on entry timing. Deploy fresh capital only upon a pullback to $206–$201 zone or confirmed breakout above $214.84; reassess at Q3 2026 earnings in late October.

Outcome

✓

Return

-0.22%

Status

scored

Maintain CVX with a 15-20% trenched trim into $212-214 supply zone rather than aggressive or conservative extremes, retaining 80-85% residual. Execute in thirds (1/3 at $211-212, 1/3 at $213-214, final 1/3 on supply zone confirmation) with cancel-if-gap-below $203 discipline. Trail stop to $203-205 and stage trimmed proceeds as dry powder for $204-207 pullback re-entry, targeting $209 over 30-60 days.

Outcome

–

Return

+0.35%

Status

scored

Trim CVX by 25-30% via trenched limit orders across three price levels ($211, $212-213, $213-214) rather than a single market order, retaining 70-75% as a residual core position; hard stop at $203 close (10 EMA) protects against structural thesis breakdown. Re-enter on either a controlled pullback to $199-203 with RSI reset to 55-60 and positive MACD histogram, or a confirmed breakout above $213.35 with volume exceeding 10M. The trim captures execution alpha on the front side while preserving meaningful participation in the structural upside given intact fundamentals (Net Debt/EBITDA 0.8x, 35 consecutive dividend increases) and Venezuela optionality not yet reflected in earnings.

Outcome

✗

Return

+2.38%

Status

scored

Underweight CVX with a 40-55% trim recommended via trenched execution across the $206-211 supply band rather than single-price or market-now execution, retaining a 45-60% residual core position protected by a $200 closing stop (10 EMA + buffer, ~4% adverse move). Explicit re-entry triggers defined upfront: add back to 70-80% target weight on confirmed breakout above $213 (volume >10M, RSI >65) or controlled pullback into $197-201 (RSI reset to 55-60, MACD histogram turning positive), with an optional December $195 put as tail hedge. Time horizon is 30-60 days tactical, with reassessment at the Fed September meeting and Q3 earnings in late October.

Outcome

✗

Return

+2.12%

Status

scored

Maintain CVX at HOLD with no fresh capital deployment at $200; hard stop at $197 close. Trim 25-50% to neutral weight if stock rallies to $205+ on Venezuela news without volume confirmation above 10M shares, but do not trim a clean breakout above $205.77 with volume confirmation. Add aggressively on pullback to $195-197 with oil holding above $78, or on $192 overshoot with oil above $80. Reassess at Q3 2026 earnings and post-Venezuela catalyst resolution.

Outcome

✓

Return

+1.05%

Status

scored

Implement Overweight via a confirmation-based staged build at $199.77, deploying 1.5–2.0% immediately then adding 1–2% on either a 50 SMA retest-hold at $185–190 with declining volume or a 10 EMA reclaim at $200.47 with RSI >55 and stabilizing MACD. Total target weight is 3–4% of portfolio (not the trader's maximum 5%), with hard stop at $185.68 on weekly close; time horizon is 60–90 days tactical with reassessment at Jackson Hole (Aug 28) and Q3 2026 earnings (late October).

Outcome

✓

Return

-0.22%

Status

scored

Maintain CVX at current portfolio weight with no fresh capital deployment at $200, converting passive Hold to an executable HOLD-PLUS framework that allows a small partial add (25% of normal size) only on confirmed $196 support hold with declining volume and RSI >55, anchored by a $190 hard stop (1.5x ATR buffer against documented gap behavior), with second tranche entry on $208-210 breakout and volume >10M.

Outcome

✓

Return

+0.16%

Status

scored

Maintain CVX at current weight with no adds at $200 — a structured Hold that converts passive discipline into active risk management. Add triggers include a daily close above 10 EMA at $200.71 on volume exceeding 8M, or a pullback into the $195-196 Bollinger middle zone. Trim 25% into the $205-207 resistance band if price stalls, with a hard structural exit on a weekly close below the 50 SMA at $184.83 on rising volume. Consider a collar (sell $215-220 calls, buy $180 puts) to define downside at minimal cost, converting the coiled technical setup into a defined outcome.

Outcome

✗

Return

-1.58%

Status

scored

Stage a phased Overweight build in CVX starting with limit orders at $200.89–$195.08 (10 EMA support), avoiding chase above $205.77, targeting 1.10–1.25x normal weight with a 1.50x hard cap and a $184.55 stop; the Q2 cash-flow inflection ($18.1B FCF, 0.56x net debt/EBITDA) and production growth (Guyana 1.2M boe/d, Tengiz +260k boe/d) support the thesis, but the 23% seven-week advance, Q2 one-offs (~$5.80 annualized vs ~$13.22 forward EPS), and Hess integration risk cap conviction at Overweight rather than Buy.

Outcome

✓

Return

-1.06%

Status

scored

CVX maintains HOLD at $205 with 3% portfolio maximum and no fresh capital deployment; the $190 stop (~$184 structural 50 SMA buffer) is correctly calibrated. Stage re-engagement triggers are set for 2% scale-in on pullback to $194-$200 with RSI cooling toward 55-60, OR 2% scale-in on confirmed breakout above $214.71 on volume >10M; both must fire or no position is taken. The rating remains under review for Q3 2026 earnings (late October) and hinges on Brent sustained above $95 or breakout confirmation.

Outcome

✓

Return

-0.24%

Status

scored

Trim approximately 25% of CVX in the $204-$208 zone, retaining a 75% core position to capture the 3.46% dividend yield and structural earnings power while reducing exposure to an estimated ~20% net-income inflation from a $2.4B "other income" swing. Two-tier stop-loss at $197.45 for tactical review and $183.83 (50 SMA) for hard invalidation, with Brent sustained below $85 for more than 2 weeks as an additional acceleration trigger.

Outcome

✓

Return

+0.00%

Status

scored

Analysts recommend holding CVX at a 2-3% portfolio weight rather than adding around the current price, citing 0.56x net debt/EBITDA, $18.1B quarterly free cash flow, and Hess-driven earnings power as structural strengths. With CVX up roughly 24% in seven weeks and trading at 15.6x forward P/E near the upper Bollinger band with RSI near 70, fresh entry is discouraged; investors above target may trim ~10% into strength. Key reassessment triggers include a weekly close below $165 (thesis invalidation), a daily close below $194.68 (review), and a close above $215 on expanding volume, plus Q3 2026 earnings and Brent's response to Hormuz headlines.

Outcome

✓

Return

+0.01%

Status

scored

Maintain CVX position at $205.74 with existing scale-in discipline unchanged—do not add at current levels despite constructive fundamentals; collect the 3.51% dividend as the "pay to wait" buffer while awaiting RSI reset below 60 in the $197-$200 zone. The HOLD rating reflects convergent analyst agreement that entry timing is poor at current price, with the trader's existing protocols ($170 stop, 3-4% sizing) already encoding the optimal risk-adjusted approach.

Outcome

✓

Return

+1.50%

Status

scored

Maintain CVX HOLD at $202.70 — three recent trim attempts at $198.50/$199.22/$200.50 failed to generate alpha (-0.1%, +1.4%, -1.8%), and current price is $0.65 above upper Bollinger with peak-cycle forward EPS $13.11, making aggressive additions premature. Wait for pullback to $193-198 (10 EMA/Bollinger mid, 1.0-1.5 ATR below) with confirmed support for first tranche add, trim 25-30% into $208-212, and maintain 3-4% energy allocation with $193 trail stop and $186 hard stop.

Outcome

✗

Return

+1.35%

Status

scored

Trim 15-20% of CVX position scaling out over 5-10 trading days in the $200-205 resistance zone, retaining 80-85% core for the 3.62% dividend and structural quality floor; stop at $183.99 (50 SMA) with re-entry triggers at $183-185 with reversal confirmation or confirmed close above $214.71 on volume >10M.

Outcome

✗

Return

+1.16%

Status

scored

Trim 15% of CVX position at $197.70, retaining 85% core, as 5.87M volume (vs 13.67M on 8/10) into $199.22 resistance signals distribution, political risk has escalated post-Pritzker's Aug 12 windfall-tax escalation, and Q2's $6.11 EPS peak is now in the rearview; stop moved from $204 to $183 (below the 50 SMA at $183.79), while rejecting covered calls at $205-$210 (caps upside when Polymarket prices 98% Hormuz non-normalization probability) and OXY rotation as momentum chasing.

Outcome

–

Return

+0.56%

Status

scored

Trim CVX by 20-25% at $198.50, moving from Neutral to Underweight versus benchmark weight, while retaining 75-80% core exposure for the 3.62% dividend yield and structural quality. Re-entry triggers are a confirmed close above $214.71 on volume >10M shares (upgrade to Neutral/Overweight) or a pullback to $183-185 50 SMA with reversal confirmation; hard stop at $214.71 breakout invalidation level.

Outcome

✓

Return

-0.03%

Status

scored

Maintain CVX at $196.66 near upper Bollinger resistance with flat momentum rather than forcing directional action. The Aggressive analyst's BUY case fails because MACD histogram rolled from +2.52 to flat (deceleration, not acceleration) and his $191 stop is only 1.1x ATR ($4.56), guaranteeing shakeout in expanding volatility. Hold sizing weights the modal outcome of range-bound time decay; reassess decisively at Q3 2026 earnings.

Outcome

✓

Return

+0.90%

Status

scored

Maintain CVX at $194.91 with a HOLD rating—neither adding into stacked resistance ($196.83/$198.50/$209) nor trimming ahead of a confirmed catalyst is warranted given the analytical deadlock. The operational framework includes symmetric trim ladders at $196.83 and $198.50, exit at $209, and accumulation zones at $189-190 and $183-185, with a hard stop at $189.50 and position sizing calibrated at $4.66 ATR per 1% portfolio risk. Macro reassessment triggers are WTI below $75 (downgrade to Underweight) and WTI above $90 for 5 days (raise trim levels).

Outcome

✗

Return

+4.48%

Status

scored

Maintain CVX at $186 with no aggressive action as risk/reward is balanced-to-mildly-negative (5-7% upside to $195-197 vs 7-10% downside to $174-180). Scale-in triggers at $180-182 and $174-178 with technical confirmations, trim into rallies at $190-191.50, and reassess at Q3 2026 earnings in late October/early November.